BiotechTubeBiotechTube
Home/Pipeline/Novel Plasma-derived Therapies

Novel Plasma-derived Therapies

Various

Pre-clinicalR&D

Key Facts

Indication
Various
Phase
Pre-clinical
Status
R&D
Company
Tiantan Bio

About Tiantan Bio

Tiantan Bio is a major player in China's biopharmaceutical sector, with a core focus on plasma-derived therapeutics and vaccines. As part of the Sinopharm Group ecosystem, it benefits from significant scale and strategic importance in public health. The company leverages its extensive plasma collection network and manufacturing capabilities to serve the large domestic market, with a pipeline that includes both biosimilars and novel biological products.

View full company profile

Therapeutic Areas

HematologyImmunologyInfectious DiseaseCritical Care

Other Various Drugs

DrugCompanyPhase
Biosimilar ProgramsRichter GedeonPhase 3
Oligonucleotide APIsBachemClinical/Commercial
Complex Injectable Generics PipelineAmphastar PharmaceuticalsANDA Filed / Development
Generic PortfolioStrides PharmaApproved
New Product LaunchesFDC IndiaDevelopment/Filing
Generic Products PortfolioCelon PharmaApproved/Commercial
New Generic Filings (e.g., for US/EU)Bliss GVS PharmaRegulatory Review
Pipeline of Complex GenericsMayne Pharma GroupDevelopment
Bag APIsChemWerthApproved
Oral APIsChemWerthApproved